摘要
目的:观察痰热清注射液、头孢哌酮舒巴坦钠治疗慢性阻塞性肺疾病(COPD)急性发作的疗效及用药安全性。方法:将206例COPD急性发作患者随机分为痰热清组(104例)、头孢哌酮舒巴坦钠组(102例)。所有患者均进行治疗前、后症状评分,疗效进行对比观察。结果:两组治疗后症状平均积分均显著低于治疗前(P<0.05)。痰热清有效率为95.20%,显著高于头孢哌酮舒巴坦钠组(77.45%),痰热清组治疗后发热、咳嗽、咯痰和气喘积分均显著性降低(P<0.05),头孢哌酮舒巴坦钠组治疗后发热、咳嗽、咯痰和气喘积分均显著性低于治疗前(P<0.05)。痰热清组不良事件发生率显著低于头孢哌酮舒巴坦钠组(P<0.05)。结论:痰热清与头孢哌酮舒巴坦钠对COPD急性发作的治疗均有效,且痰热清治疗COPD急性发作的临床疗效优于头孢哌酮舒巴坦钠,痰热清副作用少,安全有效。
Objective, To evaluate the efficacy and safety of Tanreqing injection and cefoperzone sodium and sulbactam sodium in the acute attack of COPD , Methods： Two hundred and six patients with acute attack of COPD were randomly divided into two groups and treated with vein Tanreqing injection （n = 104） and cefoperzone sodium and sulbactam sodium injection （n= 102） . Scoring of symptoms were performed in all of the patients before and after treatment. Curative effects were evaluated with the different grades. Results： The average symptomatic scores after treatments were significantly decreased compared with those of the patients in two groups before （P〈0.05）. The rates of conspicuous and tangible results in the group with Tanreqing injection （95.20%）were higher than that of cefoperzone sodium and sulbactam sodium injection （77. 45 %,P〈0. 005）. After treatment the scores of symptoms, fever, cough, phlegm spitting and shortness of breathe, were lower than before in Tanreqing injection group （P〈0. 05）, and in the group with cefoperzone sodium and sulbactam sodium injection（P〈0.05）. Moreover, the adverse reaction rate was the lower in Tanreqing injection group than in the group of cefoperzone sodium and sulbactam sodium injection group. Conclusion： The symptoms of the patients with acute attack of COPD may be remitted with all above-mentioned drugs, but Tanreqing injection is more effective than cefoperzone sodium and sulbactam sodium injection with fewer adverse reactions .
出处
《陕西医学杂志》
CAS
北大核心
2006年第9期1179-1181,共3页
Shaanxi Medical Journal
关键词
肺疾病
慢性阻塞性/诊断
肺疾病
慢性阻塞性/药物疗法
头孢哌酮/治疗
应用
obstructive/drug therapy Pulmonary disease, chronic obstructive/diagnosis Pulmonary disease, chronic Cefoperzone/t herapeutic use
